title: [Advances in thalidomide therapy for idiopathic myelofibrosis].
abstract: Idiopathic myelofibrosis a Philadelphia-negative chronic myeloproliferative disorder. Potentially curative therapies, such as stem-cell transplantation, are reserved only for a minority of patients. Currently palliative therapies such as androgen and hydroxycarbamide are commonly used but with poor results. Thalidomide has anti-angiogenic effect and also can inhibit cytokines, and therefore plays a certain role in the treatment of a subset of idiopathic myelofibrosis.
authors.affiliation: Department of General Internal Medicine, PUMC Hospital, CAMS and PUMC, Beijing 100730, China.
authors.forename: Li
authors.initials: L
authors.lastname: Song
authors.forename: Jia-Lin
authors.initials: JL
authors.lastname: Chen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D007166:Immunosuppressive Agents; D013792:Thalidomide